glp-1 who should not take Why do patients stop drugs? Should GLP-1 Drugs Be Over
Description
GLP-1s are proving their value well beyond the scale, with benefits ranging from improved glycemic control and reduced cardiovascular risk to better mobility and quality of life
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Together, these solutions create a comprehensive approach to achieving sustainable weight loss
In treating diabetes, when constipation is an issue, I already switch between Ozempic, the older GLP-1 medicines Victoza and Trulicity, and the newer Mounjaro
Now I feel lighter and more energetic
